Introduction: The clinical spectrum of gluten-sensitive enteropathy is remarkably varied and the disease can affect many extraintestinal organs and systems, including the liver. Liver involvement, which is observed in patients with gluten-sensitive enteropathy, varies from an asymptomatic increase of hepatic enzymes or non-specific reactive hepatitis (cryptogenic hepatic disorders) to chronic liver disease. The histological changes and the dynamics of enzymes are notably different after a glutenfree diet (GFD) treatment.
INTRODUCTION
Gluten-sensitive enteropathy (GE) is an autoimmune disease of the digestive system in which an abnormal reaction to gluten [1] is developed -the protein fraction in wheat, rye, barley, and to a lesser degree -in oats. The condition is one of the most widely spread gastrointestinal disorders with a large spectrum of clinical manifestations [2] .
The exact cause of the liver damage in patients with GE has not been studied well yet [3] .
However, it is known that hypertransaminasemia can be an initial manifestation of GE [4] . There are numerous hepatic diseases, which can be related to it [5] . June, 2015. Thirty-four men and 78 women between the ages of 18 and 76 were included. The control group consisted of 22 patients of whom 6 were men and 16women.
Hepatic Diseases Related to GE

RESULTS AND DISCUSSION
All patients from the studied group underwent routine laboratory biochemical testing -AST (normal range -0.0-34 IU/mL), ALT (normal range -10-35 IU/mL), alkaline phosphatase (ALP) (normal range -45-129² U/mL), bilirubin -5.0-21mmol/L. The levels above the upper limit of the range were considered proof of liver failure. Patients with proven hepatic diseases with autoimmune or viral genesis were excluded from the group in the current study. Monitoring and testing was conducted on 8 patients -3 men and 5 women with altered hepatic function. All patients were put on GFD.
Before the start of the study a detailed medical history was taken, including past diseases, medicament intake, foods with possible toxic effect, and alcohol intake. An ultrasound study of the hepatobiliary system was conducted.
The mean age of the studied patients was 26.4± 4.8 years (range 19-32 years). All of them underwent an endoscopic study and a morphologic diagnosis was established using the Marsh-Oberhuber classification.
The distribution was as follows: Marsh 2 -1, Marsh3a -3, Marsh3b -3, Marsh3c -1. No IgA deficit was established in any of the patients. At the start of the study only one of the female patients had increased levels of total bilirubin, and the rest had normal initial levels with a mean level of 10.5 ± 0.5 (range 7-30).
All 8 patients had abnormal hepatic enzyme levels. The mean ASAT and ALAT levels (±SD) were 62.6 ± 16.5IU/mL(range -31-186IU/mL) and 69.3± 9.3IU/mL (range 63-432IU/mL), respectively. The mean alkaline phosphatase concentration (± SD) was 280.3±118.7mmol/ L (range -160-428mmol/L).
After a six-month course of GFD, the hepatic enzyme levels decreased to normal values in all patients -24.5±5.1IU/mL and 18-37IU/mL in women (p -0.04 ); and 28.6± 6 IU/mL and 22-33 IU/mL in men, although no statistically significant differences were established (p-0.33). The alkaline phosphatase concentration decreased to 180.3± 50.6 mmol/L (range 180-280mmol/L), 6 months after GFD. The differences from the pre-GFD levels had no statistical significance (p-0.09). The predominant reactive hepatitis in this cohort -7%, had complete resolution after GFD. Table 1 presents the serum levels of bilirubin, AST, ALT, and ALP, before and after GFD.
Several studies report percentages that are a little higher -for example Disky et al. [9] report 15% hypertransaminasemia among the newly diagnosed patients with GE. Abdo et al. [10] report 9% hypertransaminasemia. It is possible that this not-so-striking difference from our study is due to the fact that the Bulgarian population might consume larger quantities of alcohol and have a higher incidence of steatohepatitis compared to the other populations.
One of the cases was of particular interest. A young woman presented at the clinic with a severe form of malabsorption syndrome, acute reactive hepatitis (all possibilities for an underlying hepatic disease were excluded). In her case, after timely diagnosis and diet therapy, full resolution of the symptoms and biochemical indicators was observed, starting as early as the third month.
CONCLUSION Liver abnormalities varying from hepatic enzyme level changes to liver failure at the time of GE diagnosis can be treated with GFD [9] . Its influence of the severity of the rest of the hepatic diseases, such as autoimmune hepatitis, is still not clear. Regardless of its effect on the concomitant hepatic disorders, GFD is necessary for the improvement of GE symptoms and all long-term consequences [7] . The lack of enough proof does not undermine the fact that clinicians should consider GE as a diagnosis in the presence of hypertransaminasemia and a lack of other causes of liver failure [11, 12] . We think that GFD  GFD  GFD  GFD  GFD  GFD  GFD  GFD   1  21  M  8  7  66  24  81  31  243  219   2  19  M  11  9  48  30  76  23  160  148   3  29  M  10  9  31  22  72  27  260  216   4  24  F  7  8  55  21  63  26  328  210   5  33  F  11  9  68  37  108  33  330  220   6  27  F  11  7  55  31  87  30  321  280   7  34  F  30  20  186  31  432  33  428  180   8  30  F  11  10  58  18  73  22  298  186 
